Nathan Weinstein

Stock Analyst at Aegis Capital

(0.28)
# 4,390
Out of 5,157 analysts
59
Total ratings
13.79%
Success rate
-24.81%
Average return

Stocks Rated by Nathan Weinstein

Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100$80
Current: $0.75
Upside: +10,553.88%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400$300
Current: $8.90
Upside: +3,270.79%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9$6
Current: $0.20
Upside: +2,860.04%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40$35
Current: $1.45
Upside: +2,313.79%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $1.93
Upside: +210.88%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35$30
Current: $3.40
Upside: +782.35%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $11.94
Upside: -16.25%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63$49
Current: $17.22
Upside: +184.55%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000$1,800
Current: $1.97
Upside: +91,270.56%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $8.51
Upside: +25,281.90%
Initiates: Buy
Price Target: $120
Current: $1.95
Upside: +6,053.85%
Maintains: Buy
Price Target: $9$10
Current: $0.57
Upside: +1,642.77%
Maintains: Buy
Price Target: $60$56
Current: $26.96
Upside: +107.72%
Maintains: Buy
Price Target: $26$27
Current: $4.06
Upside: +565.02%
Maintains: Buy
Price Target: $40$35
Current: $0.89
Upside: +3,823.77%
Initiates: Buy
Price Target: $12
Current: $1.39
Upside: +763.31%
Initiates: Buy
Price Target: $75
Current: $26.57
Upside: +182.27%
Maintains: Buy
Price Target: $104$88
Current: $2.02
Upside: +4,256.44%
Initiates: Buy
Price Target: $180
Current: $0.60
Upside: +30,020.48%
Maintains: Buy
Price Target: $195$135
Current: $12.71
Upside: +962.16%
Initiates: Buy
Price Target: $14
Current: $6.65
Upside: +110.53%
Maintains: Buy
Price Target: $180$220
Current: $16.37
Upside: +1,243.92%
Initiates: Buy
Price Target: $8.5
Current: $2.94
Upside: +189.12%